These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28753395)

  • 1. Neurocognitive Impairment in a Chronically Well-Suppressed HIV-Infected Population: The Dutch TREVI Cohort Study.
    van den Dries LWJ; Wagener MN; Jiskoot LC; Visser M; Robertson KR; Adriani KS; van Gorp ECM
    AIDS Patient Care STDS; 2017 Aug; 31(8):329-334. PubMed ID: 28753395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study.
    Lawler K; Mosepele M; Ratcliffe S; Seloilwe E; Steele K; Nthobatsang R; Steenhoff A
    J Int AIDS Soc; 2010 Apr; 13():15. PubMed ID: 20406460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.
    Ellis RJ; Badiee J; Vaida F; Letendre S; Heaton RK; Clifford D; Collier AC; Gelman B; McArthur J; Morgello S; McCutchan JA; Grant I;
    AIDS; 2011 Sep; 25(14):1747-51. PubMed ID: 21750419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychological Assessment of 412 HIV-Infected Individuals in São Paulo, Brazil.
    Gascón MRP; Vidal JE; Mazzaro YM; Smid J; Marcusso RMN; Capitão CG; Coutinho EM; Benute GRG; De Lucia MCS; de Oliveira ACP
    AIDS Patient Care STDS; 2018 Jan; 32(1):1-8. PubMed ID: 29323557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic.
    Marin-Webb V; Jessen H; Kopp U; Jessen AB; Hahn K
    PLoS One; 2016; 11(12):e0168225. PubMed ID: 27992497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Good neurocognitive performance measured by the international HIV dementia scale in early HIV-1 infection.
    Lopardo GD; Bissio E; Iannella Mdel C; Crespo AD; Garone DB; Cassetti LI
    J Acquir Immune Defic Syndr; 2009 Dec; 52(4):488-92. PubMed ID: 19654553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the use of the QPC cognitive complaints questionnaire relevant for the screening strategy of HIV-Associated neurocognitive disorders?
    Zaegel-Faucher O; Laroche H; Tixier M; Morisseau V; Obry-Roguet V; Poizot-Martin I
    AIDS Care; 2021 Mar; 33(3):389-397. PubMed ID: 32279542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care.
    McCombe JA; Vivithanaporn P; Gill MJ; Power C
    HIV Med; 2013 Feb; 14(2):99-107. PubMed ID: 22994556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Montreal Cognitive Assessment-Basic (MoCA-B) is not a reliable screening tool for cognitive decline in HIV patients receiving combination antiretroviral therapy in rural South Africa.
    Hakkers CS; Beunders AJM; Ensing MHM; Barth RE; Boelema S; Devillé WLJ; Tempelman HA; Coutinho RA; Hoepelman AIM; Arends JE; van Zandvoort MJE
    Int J Infect Dis; 2018 Feb; 67():36-40. PubMed ID: 29183843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.
    Temereanca A; Ene L; Rosca A; Diaconu CC; Luca A; Burlacu R; Radoi R; Bulacu-Talnariu A; Marcotte TD; Achim CL; Ruta S
    AIDS Res Hum Retroviruses; 2020 May; 36(5):367-372. PubMed ID: 31476875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients.
    Cysique LA; Maruff P; Brew BJ
    Neurology; 2006 May; 66(9):1447-50. PubMed ID: 16682686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive screening in treatment-naïve HIV-infected individuals in Hong Kong - a single center study.
    Chan FCC; Chan P; Chan I; Chan A; Tang THC; Lam W; Fong WC; Lee MP; Li P; Chan GHF
    BMC Infect Dis; 2019 Feb; 19(1):156. PubMed ID: 30760220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for HIV-associated dementia in South Africa: potentials and pitfalls of task-shifting.
    Robbins RN; Remien RH; Mellins CA; Joska JA; Stein DJ
    AIDS Patient Care STDS; 2011 Oct; 25(10):587-93. PubMed ID: 21919734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.
    Carvalhal A; Gill MJ; Letendre SL; Rachlis A; Bekele T; Raboud J; Burchell A; Rourke SB;
    J Neurovirol; 2016 Jun; 22(3):349-57. PubMed ID: 26572786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of Five Brief Screening Tools for HIV-Associated Neurocognitive Disorders in the USA and South Africa.
    Joska JA; Witten J; Thomas KG; Robertson C; Casson-Crook M; Roosa H; Creighton J; Lyons J; McArthur J; Sacktor NC
    AIDS Behav; 2016 Aug; 20(8):1621-31. PubMed ID: 26860536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa.
    Choi Y; Townend J; Vincent T; Zaidi I; Sarge-Njie R; Jaye A; Clifford DB
    J Neurovirol; 2011 Apr; 17(2):166-75. PubMed ID: 21424866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An initial screening for HIV-associated neurocognitive disorders of HIV-1 infected patients in China.
    Zhang Y; Qiao L; Ding W; Wei F; Zhao Q; Wang X; Shi Y; Li N; Smith D; Chen D
    J Neurovirol; 2012 Apr; 18(2):120-6. PubMed ID: 22411002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy.
    Skinner S; Adewale AJ; DeBlock L; Gill MJ; Power C
    HIV Med; 2009 Apr; 10(4):246-52. PubMed ID: 19187172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment.
    Tozzi V; Balestra P; Galgani S; Narciso P; Ferri F; Sebastiani G; D'Amato C; Affricano C; Pigorini F; Pau FM; De Felici A; Benedetto A
    AIDS; 1999 Oct; 13(14):1889-97. PubMed ID: 10513647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.
    Cysique LA; Brew BJ
    J Neurovirol; 2011 Apr; 17(2):176-83. PubMed ID: 21416169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.